Jing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jing Li has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
Klaus Charisse
Alnylam Pharmaceuticals, Cambridge, USA
4 shared publicationsChris Tran
Alnylam Pharmaceuticals Inc., Cambridge, MA02142, USA
3 shared publicationsIvan Zlatev
Alnylam Pharmaceuticals Inc., Cambridge, MA02142, USA
3 shared publicationsJing-Tao Wu
Alnylam Pharmaceuticals, Cambridge, USA
3 shared publicationsKevin Fitzgerald
Alnylam Pharmaceuticals, Cambridge, USA
3 shared publications- Krishna Aluri
Drug Metabolism and Pharmacokinetics, Oncology R&D, AstraZeneca , 35 Gatehouse Park Drive, Waltham, MA 02451
3 shared publications
Latest Publications
- Top Cited Papers
- 2 June 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (10) , 1500-1508
Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new delivery solutions are needed to target additional organs. Here we show that conjugation of 2′-O-hexadecyl (C16) to siRNAs enables safe, potent and durable silencing in the central nervous system (CNS), eye and lung in rodents and non-human primates with broad cell type specificity. We show that intrathecally or intracerebroventricularly delivered C16-siRNAs were active across CNS regions and cell types, with sustained RNA interference (RNAi) activity for at least 3 months. Similarly, intravitreal administration to the eye or intranasal administration to the lung resulted in a potent and durable knockdown. The preclinical efficacy of an siRNA targeting the amyloid precursor protein was evaluated through intracerebroventricular dosing in a mouse model of Alzheimer’s disease, resulting in amelioration of physiological and behavioral deficits. Altogether, C16 conjugation of siRNAs has the potential for safe therapeutic silencing of target genes outside the liver with infrequent dosing.
- 2 June 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (10) , 1500-1508
Top Cited PapersExpanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates
Therapeutics based on short interfering RNAs (siRNAs) delivered to hepatocytes have been approved, but new delivery solutions are needed to target additional organs. Here we show that conjugation of 2′-O-hexadecyl (C16) to siRNAs enables safe, potent and durable silencing in the central nervous system (CNS), eye and lung in rodents and non-human primates with broad cell type specificity. We show that intrathecally or intracerebroventricularly delivered C16-siRNAs were active across CNS regions and cell types, with sustained RNA interference (RNAi) activity for at least 3 months. Similarly, intravitreal administration to the eye or intranasal administration to the lung resulted in a potent and durable knockdown. The preclinical efficacy of an siRNA targeting the amyloid precursor protein was evaluated through intracerebroventricular dosing in a mouse model of Alzheimer’s disease, resulting in amelioration of physiological and behavioral deficits. Altogether, C16 conjugation of siRNAs has the potential for safe therapeutic silencing of target genes outside the liver with infrequent dosing.
- Open Access
- 21 October 2021
- Published by Springer Nature in Research Square
Expanding the Reach of RNAi Therapeutics with Next Generation Lipophilic siRNA Conjugates
RNA interference (RNAi) therapeutics are a new class of medicines that can address unmet medical needs by silencing disease-causing gene transcripts. While delivery of short interfering RNAs (siRNAs) to hepatocytes has yielded multiple drug approvals, novel delivery solutions are needed to expand the reach of RNAi therapeutics. Here we report that conjugation of 2'-O-hexadecyl (C16) to siRNAs enables efficient silencing in the central nervous system (CNS), eye, and lung of multiple nonclinical species with broad cell type specificity. Intrathecally delivered C16-siRNAs are active across CNS regions and cell types, with sustained silencing for at least three months, which is an especially important outcome considering the challenging dosing route. Similarly, intravitreal and intranasal administration of C16-siRNAs resulted in potent and sustained knockdown in the eye and lung, respectively. Efficient delivery facilitated through C16 conjugation to optimized siRNA designs has enabled candidate selection for investigational human clinical trials assessing therapeutic silencing beyond the liver with infrequent (e.g. bi-annual) dosing.
- 21 October 2021
- Published by Springer Nature in Research Square
Open AccessExpanding the Reach of RNAi Therapeutics with Next Generation Lipophilic siRNA Conjugates
RNA interference (RNAi) therapeutics are a new class of medicines that can address unmet medical needs by silencing disease-causing gene transcripts. While delivery of short interfering RNAs (siRNAs) to hepatocytes has yielded multiple drug approvals, novel delivery solutions are needed to expand the reach of RNAi therapeutics. Here we report that conjugation of 2'-O-hexadecyl (C16) to siRNAs enables efficient silencing in the central nervous system (CNS), eye, and lung of multiple nonclinical species with broad cell type specificity. Intrathecally delivered C16-siRNAs are active across CNS regions and cell types, with sustained silencing for at least three months, which is an especially important outcome considering the challenging dosing route. Similarly, intravitreal and intranasal administration of C16-siRNAs resulted in potent and sustained knockdown in the eye and lung, respectively. Efficient delivery facilitated through C16 conjugation to optimized siRNA designs has enabled candidate selection for investigational human clinical trials assessing therapeutic silencing beyond the liver with infrequent (e.g. bi-annual) dosing.
- 1 November 2019
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (21) , 1955-1965
Discovery of a Novel Deaminated Metabolite of a Single-Stranded Oligonucleotide In Vivo by Mass Spectrometry
Aim: A novel single-stranded deaminated oligonucleotide metabolite resulting from a REVERSIR™ oligonucleotide was discovered and identified in monkey liver after subcutaneous administration. Result...
- 1 November 2019
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (21) , 1955-1965
Discovery of a Novel Deaminated Metabolite of a Single-Stranded Oligonucleotide In Vivo by Mass Spectrometry
Aim: A novel single-stranded deaminated oligonucleotide metabolite resulting from a REVERSIR™ oligonucleotide was discovered and identified in monkey liver after subcutaneous administration. Result...
- 1 November 2019
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (21) , 1967-1980
Oligonucleotide Quantification and Metabolite Profiling by High-Resolution and Accurate Mass Spectrometry
Aim: Advancements in RNA interference therapeutics have triggered development of improved bioanalytical methods for oligonucleotide metabolite profiling and high-throughput quantification in biolog...
- 1 November 2019
- Published by Taylor & Francis in Bioanalysis
- Vol. 11 (21) , 1967-1980
Oligonucleotide Quantification and Metabolite Profiling by High-Resolution and Accurate Mass Spectrometry
Aim: Advancements in RNA interference therapeutics have triggered development of improved bioanalytical methods for oligonucleotide metabolite profiling and high-throughput quantification in biolog...
- Open Access
- 1 March 2019
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 47 (7) , 3306-3320
Safety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
For oligonucleotide therapeutics, chemical modifications of the sugar-phosphate backbone are frequently used to confer drug-like properties. Because 2′-deoxy-2′-fluoro (2′-F) nucleotides are not known to occur naturally, their safety profile was assessed when used in revusiran and ALN-TTRSC02, two short interfering RNAs (siRNAs), of the same sequence but different chemical modification pattern and metabolic stability, conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2′-F-monomer metabolites was low and transient in rats and humans. In vitro, 2′-F-nucleoside 5′-triphosphates were neither inhibitors nor preferred substrates for human polymerases, and no obligate or non-obligate chain termination was observed. Modest effects on cell viability and mitochondrial DNA were observed in vitro in a subset of cell types at high concentrations of 2′-F-nucleosides, typically not attained in vivo. No apparent functional impact on mitochondria and no significant accumulation of 2′-F-monomers were observed after weekly administration of two GalNAc–siRNA conjugates in rats for ∼2 years. Taken together, the results support the conclusion that 2′-F nucleotides can be safely applied for the design of metabolically stabilized therapeutic GalNAc–siRNAs with favorable potency and prolonged duration of activity allowing for low dose and infrequent dosing.
- 1 March 2019
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 47 (7) , 3306-3320
Open AccessSafety evaluation of 2′-deoxy-2′-fluoro nucleotides in GalNAc-siRNA conjugates
For oligonucleotide therapeutics, chemical modifications of the sugar-phosphate backbone are frequently used to confer drug-like properties. Because 2′-deoxy-2′-fluoro (2′-F) nucleotides are not known to occur naturally, their safety profile was assessed when used in revusiran and ALN-TTRSC02, two short interfering RNAs (siRNAs), of the same sequence but different chemical modification pattern and metabolic stability, conjugated to an N-acetylgalactosamine (GalNAc) ligand for targeted delivery to hepatocytes. Exposure to 2′-F-monomer metabolites was low and transient in rats and humans. In vitro, 2′-F-nucleoside 5′-triphosphates were neither inhibitors nor preferred substrates for human polymerases, and no obligate or non-obligate chain termination was observed. Modest effects on cell viability and mitochondrial DNA were observed in vitro in a subset of cell types at high concentrations of 2′-F-nucleosides, typically not attained in vivo. No apparent functional impact on mitochondria and no significant accumulation of 2′-F-monomers were observed after weekly administration of two GalNAc–siRNA conjugates in rats for ∼2 years. Taken together, the results support the conclusion that 2′-F nucleotides can be safely applied for the design of metabolically stabilized therapeutic GalNAc–siRNAs with favorable potency and prolonged duration of activity allowing for low dose and infrequent dosing.
- Open Access
- 1 March 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (12) , 8061-8073
Sialylneolacto-N-tetraose c (LSTc)-bearing Liposomal Decoys Capture Influenza A Virus
- 1 March 2013
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 288 (12) , 8061-8073
Open AccessSialylneolacto-N-tetraose c (LSTc)-bearing Liposomal Decoys Capture Influenza A Virus
- Open Access
- 29 May 2012
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 444 (3) , 429-435
Glycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors
The glycoprotein HA (haemagglutinin) on the surface of influenza A virus plays a central role in recognition and binding to specific host cell-surface glycan receptors and in fusion of viral membrane to the host nuclear membrane during viral replication. Given the abundance of HA on the viral surface, this protein is also the primary target for host innate and adaptive immune responses. Although addition of glycosylation sites on HA are a part of viral evolution to evade the host immune responses, there are specific glycosylation sites that are conserved during most of the evolution of the virus. In the present study, it was demonstrated that one such conserved glycosylation site at Asn(91) in H1N1 HA critically governs the glycan receptor-binding specificity and hence would potentially impinge on the host adaptation of the virus.
- 29 May 2012
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 444 (3) , 429-435
Open AccessGlycosylation at Asn91 of H1N1 haemagglutinin affects binding to glycan receptors
The glycoprotein HA (haemagglutinin) on the surface of influenza A virus plays a central role in recognition and binding to specific host cell-surface glycan receptors and in fusion of viral membrane to the host nuclear membrane during viral replication. Given the abundance of HA on the viral surface, this protein is also the primary target for host innate and adaptive immune responses. Although addition of glycosylation sites on HA are a part of viral evolution to evade the host immune responses, there are specific glycosylation sites that are conserved during most of the evolution of the virus. In the present study, it was demonstrated that one such conserved glycosylation site at Asn(91) in H1N1 HA critically governs the glycan receptor-binding specificity and hence would potentially impinge on the host adaptation of the virus.
- Open Access
- 4 December 2011
- Published by Springer Nature in Nature Chemistry
- Vol. 4 (1) , 45-51
Three-component reaction discovery enabled by mass spectrometry of self-assembled monolayers
- 4 December 2011
- Published by Springer Nature in Nature Chemistry
- Vol. 4 (1) , 45-51
Open AccessThree-component reaction discovery enabled by mass spectrometry of self-assembled monolayers
- Open Access
- 3 November 2010
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 114 (46) , 15113-15118
Rate Enhancement of an Interfacial Biochemical Reaction through Localization of Substrate and Enzyme by an Adaptor Domain
This paper describes a model system to characterize the rate enhancement that stems from localization of an enzyme with its substrate. The approach is based on a self-assembled monolayer that presents a substrate for the serine esterase cutinase along with a peptide ligand for an SH2 adaptor domain. The monolayer is treated with a fusion protein of cutinase and the SH2 domain, and the rate for the interfacial reaction is monitored using cyclic voltammetry. The rate is approximately 30-fold greater for monolayers that present the ligand for the SH2 domain than for those that omit the ligand. The rate enhancement is due to the interaction of the adaptor domain with the immobilized ligand. Further, the rate enhancement increases with the densities of both the ligand and the substrate. This example provides a well-defined model system for quantitatively assessing the magnitude of rate enhancement that is possible with colocalization of an enzyme with its substrate and may be particularly significant for understanding the signaling events that rely on enzyme localization at the cell membrane.
- 3 November 2010
- Published by American Chemical Society (ACS) in The Journal of Physical Chemistry B
- Vol. 114 (46) , 15113-15118
Open AccessRate Enhancement of an Interfacial Biochemical Reaction through Localization of Substrate and Enzyme by an Adaptor Domain
This paper describes a model system to characterize the rate enhancement that stems from localization of an enzyme with its substrate. The approach is based on a self-assembled monolayer that presents a substrate for the serine esterase cutinase along with a peptide ligand for an SH2 adaptor domain. The monolayer is treated with a fusion protein of cutinase and the SH2 domain, and the rate for the interfacial reaction is monitored using cyclic voltammetry. The rate is approximately 30-fold greater for monolayers that present the ligand for the SH2 domain than for those that omit the ligand. The rate enhancement is due to the interaction of the adaptor domain with the immobilized ligand. Further, the rate enhancement increases with the densities of both the ligand and the substrate. This example provides a well-defined model system for quantitatively assessing the magnitude of rate enhancement that is possible with colocalization of an enzyme with its substrate and may be particularly significant for understanding the signaling events that rely on enzyme localization at the cell membrane.